The Authors found that STAT6 ASO combined with radiotherapy slowed growth of both primary and abscopal tumors, decreased lung metastases, and extended survival which may be an alternative therapeutic approach for patients with immune-resistant NSCLC [40]. Here, STAT6 is linked to non-small cell lung carcinoma.